Revolutionizing Allogeneic Cellular Therapeutics

Cellphire Therapeutics is developing next generation allogeneic therapeutics that harness the inherent biological capabilities of human cells. Our therapeutic platform consists of three technological capabilities:

• Stabilizing human cells for extended shelf life with rapid restoration, easy preparation and use
• Pooling cells from many donors ensuring consistent quality, safety, and scalable production
• Formulating cell therapies to achieve a desired biological outcome

‍Our lead product, Thrombosomes®, currently in Phase 2 clinical trials, is the starting point on the way to achieving our Vision. The technologies developed while creating Thrombosomes® enable a host of novel cellular therapies previously not possible.